Chembio Diagnostics (Chembio Diagnostics) COGS-to-Revenue : 0.61 (As of Dec. 2022)

View and export this data going back to 2004. Start your Free Trial

What is Chembio Diagnostics COGS-to-Revenue?

Chembio Diagnostics's Cost of Goods Sold for the three months ended in Dec. 2022 was $5.61 Mil. Its Revenue for the three months ended in Dec. 2022 was $9.16 Mil.

Chembio Diagnostics's COGS to Revenue for the three months ended in Dec. 2022 was 0.61.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Chembio Diagnostics's Gross Margin % for the three months ended in Dec. 2022 was 38.78%.

Chembio Diagnostics COGS-to-Revenue Historical Data

The historical data trend for Chembio Diagnostics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chembio Diagnostics COGS-to-Revenue Chart

Chembio Diagnostics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

Get a 7-Day Free Trial

0.65

0.66

0.78

0.93

0.80

Chembio Diagnostics Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
COGS-to-Revenue	Get a 7-Day Free Trial															1.07	0.81	0.88	0.86	0.61

Chembio Diagnostics COGS-to-Revenue Calculation

Chembio Diagnostics's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	38.578	/	48.34
	=	0.80

Chembio Diagnostics's COGS to Revenue for the quarter that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	5.609	/	9.162
	=	0.61

Chembio Diagnostics (NAS:CEMI) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Chembio Diagnostics's Gross Margin % for the three months ended in Dec. 2022 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	5.609 / 9.162
	=	38.78 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Chembio Diagnostics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Chembio Diagnostics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Chembio Diagnostics (Chembio Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Chembio Diagnostics Inc (NAS:CEMI) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

3661 Horseblock Road, Medford, NY, USA, 11763

Website

http://www.chembio.com

Chembio Diagnostics Inc is a company that develops, manufactures, and commercializes point-of-care diagnostic tests that detect infectious diseases. The products of the company include rapid tests for the detection of HIV 1/2 antibodies and a multiplex rapid test for the detection of HIV and syphilis antibodies. The company offered rapid medical tests that are offered in Africa, Asia, Europe, and the Middle East, Latin America and the United States, of which key revenue is derived from Latin America.

Executives

Perceptive Credit Advisors, Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Leslie Teso-lichtman	director	C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Charles Caso	officer: See remarks	C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Paul Angelico	officer: See remarks	C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Lawrence J. Steenvoorden	officer: See remarks	C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
David William Bespalko	director	29 CEDAR DRIVE, ALLENDALE NJ 07401
David Acheson	director	C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Richard Eberly	officer: See Remarks	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John Gary Potthoff	director	6140 SPANISH OAKS CLUB BLVD., AUSTIN TX 78738
Javan Esfandiari	officer: Senior Vice President	3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Robert Passas	officer: See Remarks	3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Polan Mary Lake Ph D	director	STANFORD UNIVERSITY SCHOOL OF MEDICINE, 300 PASTAUR DR ROOM HH333, STANFORD CA 94305-5317
Neil A Goldman	officer: Executive VP and CFO	3661 HORSEBLOCK RD, MEDFORD NY 11763